152 related articles for article (PubMed ID: 33028487)
1. Two-dimensional parametric parenchymal blood flow in transarterial chemoembolisation for hepatocellular carcinoma: perfusion change quantification and tumour response prediction at 3 months post-intervention.
Becker LS; Maschke SK; Dewald CLA; Meine TC; Winther HBM; Kirstein MM; Kloeckner R; Meyer BC; Wacker F; Hinrichs JB
Clin Radiol; 2021 Feb; 76(2):160.e27-160.e33. PubMed ID: 33028487
[TBL] [Abstract][Full Text] [Related]
2. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of angiographic perfusion reduction using color-coded digital subtraction angiography during transarterial chemoembolization.
Wang J; Cheng JJ; Huang KY; Zhuang ZG; Zhang XB; Chi JC; Hua XL; Xu JR
Abdom Radiol (NY); 2016 Mar; 41(3):545-52. PubMed ID: 27039326
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of perfusion changes using a 2D Parametric Parenchymal Blood Flow technique with automated vessel suppression following partial spleen embolization in patients with hypersplenism and portal hypertension.
Meine TC; Maschke SK; Kirstein MM; Jaeckel E; Lena BS; Werncke T; Dewald CLA; Wacker FK; Meyer BC; Hinrichs JB
Medicine (Baltimore); 2021 Feb; 100(7):e24783. PubMed ID: 33607830
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
6. Parenchymal Liver Blood Volume and Dynamic Volume Perfusion CT Measurements of Hepatocellular Carcinoma in Patients Undergoing Transarterial Chemoembolization.
Rathmann N; Kara K; Budjan J; Henzler T; Smakic A; Schoenberg SO; Diehl SJ
Anticancer Res; 2017 Oct; 37(10):5681-5685. PubMed ID: 28982886
[TBL] [Abstract][Full Text] [Related]
7. Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation.
Kaufmann S; Horger T; Oelker A; Beck S; Schulze M; Nikolaou K; Ketelsen D; Horger M
Eur J Radiol; 2015 Dec; 84(12):2548-54. PubMed ID: 26428842
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a newly developed 2D parametric parenchymal blood flow technique with an automated vessel suppression algorithm in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty.
Maschke SK; Winther HMB; Meine T; Werncke T; Olsson KM; Hoeper MM; Baumgart J; Wacker FK; Meyer BC; Renne J; Hinrichs JB
Clin Radiol; 2019 Jun; 74(6):437-444. PubMed ID: 30890260
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.
Chen G; Ma DQ; He W; Zhang BF; Zhao LQ
World J Gastroenterol; 2008 Oct; 14(37):5738-43. PubMed ID: 18837093
[TBL] [Abstract][Full Text] [Related]
11. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone.
Peisen F; Maurer M; Grosse U; Nikolaou K; Syha R; Artzner C; Bitzer M; Horger M; Grözinger G
Eur J Radiol; 2021 Jul; 140():109768. PubMed ID: 33991970
[TBL] [Abstract][Full Text] [Related]
12. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
13. Survival, tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma.
Huo YR; Xiang H; Chan MV; Chan C
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):802-811. PubMed ID: 31709778
[TBL] [Abstract][Full Text] [Related]
14. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
[TBL] [Abstract][Full Text] [Related]
15. Change in Perfusion Angiography During Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Predicts Short-Term Outcomes.
Kim HO; Yim NY; Kim JK; Kang YJ; Lee BC; Kim JW
AJR Am J Roentgenol; 2019 Oct; 213(4):746-754. PubMed ID: 31039020
[No Abstract] [Full Text] [Related]
16. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
Gross A; Albrecht T
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):402-410. PubMed ID: 31705244
[TBL] [Abstract][Full Text] [Related]
17. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter?
Lee SY; Ou HY; Yu CY; Huang TL; Tsang LL; Cheng YF
Diagn Interv Radiol; 2020 May; 26(3):230-235. PubMed ID: 32352922
[TBL] [Abstract][Full Text] [Related]
19. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings.
Bayle M; Clerc-Urmès I; Ayav A; Bronowicki JP; Petit I; Orry X; Laurent V
Abdom Radiol (NY); 2019 Jan; 44(1):85-94. PubMed ID: 30054686
[TBL] [Abstract][Full Text] [Related]
20. Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study.
Pauwels X; Azahaf M; Lassailly G; Sergent G; Buob D; Truant S; Boleslawski E; Louvet A; Gnemmi V; Canva V; Mathurin P; Pruvot FR; Leteurtre E; Ernst O; Dharancy S
Cardiovasc Intervent Radiol; 2015 Jun; 38(3):685-92. PubMed ID: 25342136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
